NCT00198432

Chemoradiotherapy of NSCLC Stage IIIB

Randomized Phase II Study Evaluating an Induction Chemotherapy Followed by a Concomitant Chemoradiotherapy and a Concomitant Chemoradiotherapy Followed by a Consolidation Chemotherapy Among Patients With NSCLC Stage III Not Resectable

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 130 (planned)
• Sponsor: Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a consolidation chemotherapy.

Detailed description

Chemotherapy: C = Cisplatine : 80 mg/m² P = Paclitaxel : 200 mg/m² N = Vinorelbine : 15 mg/m² Radiotherapy: 66 Gy with 33 fractions (2 Gy/fraction, 1 fraction/day, 6,5 weeks) High energy Photons X (\>= 9MV)

Conditions

• NSCLC Stage IIIB
• Concomitant Radiochemotherapy

Interventions

Type	Name	Description
DRUG	Paclitaxel, vinorelbine, cisplatin

Timeline

• Start date: 2002-03-01
• Completion: 2006-12-01
• First posted: 2005-09-20
• Last updated: 2016-03-10

Locations

1 site across 1 country: France